VAXCYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
VAXCYTE, INC. (PCVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $35.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-24
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $2.40M, a 82.98% decline year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $31.00M, a 18.64% decline year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $37.70M, a 280.81% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $40.80M, a 716.00% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $35.00M, a 73.22% decline from fiscal 2024.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $130.70M, a 516.51% increase from fiscal 2023.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $21.20M, a 37.65% decline from fiscal 2022.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $34.00M, a 79.89% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $35.00M 10-K · filed 2026-02-24 | |||
| 2025-06-30 | $2.40M 10-Q · filed 2025-08-06 | $33.30M 10-Q · filed 2025-08-06 | $71.10M derived: sum of 3 quarters · filed 2026-02-24 | $111.90M derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-03-31 | $31.00M 10-Q · filed 2025-05-07 | $68.70M derived: sum of 2 quarters · filed 2026-02-24 | $109.50M derived: sum of 3 quarters · filed 2026-02-24 | $123.60M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | $37.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $78.50M derived: sum of 2 quarters · filed 2026-02-24 | $92.60M derived: sum of 3 quarters · filed 2026-02-24 | $130.70M 10-K · filed 2026-02-24 |
| 2024-09-30 | $40.80M 10-Q · filed 2024-11-05 | $54.90M derived: sum of 2 quarters · filed 2025-08-06 | $93.00M 10-Q · filed 2024-11-05 | $102.90M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $14.10M 10-Q · filed 2025-08-06 | $52.20M 10-Q · filed 2025-08-06 | $62.10M derived: sum of 3 quarters · filed 2026-02-24 | $67.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $38.10M 10-Q · filed 2025-05-07 | $48.00M derived: sum of 2 quarters · filed 2026-02-24 | $53.00M derived: sum of 3 quarters · filed 2026-02-24 | $55.40M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $9.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $14.90M derived: sum of 2 quarters · filed 2026-02-24 | $17.30M derived: sum of 3 quarters · filed 2026-02-24 | $21.20M 10-K · filed 2026-02-24 |
| 2023-09-30 | $5.00M 10-Q · filed 2024-11-05 | $7.40M derived: sum of 2 quarters · filed 2024-11-05 | $11.30M 10-Q · filed 2024-11-05 | $37.80M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $2.40M 10-Q · filed 2024-08-06 | $6.30M 10-Q · filed 2024-08-06 | $32.80M derived: sum of 3 quarters · filed 2025-02-25 | $36.80M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $3.80M 10-Q · filed 2024-05-08 | $30.40M derived: sum of 2 quarters · filed 2025-02-25 | $34.40M derived: sum of 3 quarters · filed 2025-02-25 | $35.90M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $26.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $30.60M derived: sum of 2 quarters · filed 2025-02-25 | $32.10M derived: sum of 3 quarters · filed 2025-02-25 | $34.00M 10-K · filed 2025-02-25 |
| 2022-09-30 | $4.00M 10-Q · filed 2023-11-06 | $5.50M derived: sum of 2 quarters · filed 2023-11-06 | $7.40M 10-Q · filed 2023-11-06 | $13.80M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $1.50M 10-Q · filed 2023-08-08 | $3.40M 10-Q · filed 2023-08-08 | $9.80M derived: sum of 3 quarters · filed 2024-02-27 | $12.30M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $1.80M 10-Q · filed 2023-05-08 | $8.30M derived: sum of 2 quarters · filed 2024-02-27 | $10.80M derived: sum of 3 quarters · filed 2024-02-27 | $14.30M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $9.00M derived: sum of 2 quarters · filed 2024-02-27 | $12.50M derived: sum of 3 quarters · filed 2024-02-27 | $18.90M 10-K · filed 2024-02-27 |
| 2021-09-30 | $2.50M 10-Q · filed 2022-11-07 | $6.00M derived: sum of 2 quarters · filed 2022-11-07 | $12.40M 10-Q · filed 2022-11-07 | $15.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $3.50M 10-Q · filed 2022-08-08 | $9.90M 10-Q · filed 2022-08-08 | $12.60M derived: sum of 3 quarters · filed 2023-02-27 | $15.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $6.40M 10-Q · filed 2022-05-09 | $9.10M derived: sum of 2 quarters · filed 2023-02-27 | $11.60M derived: sum of 3 quarters · filed 2023-02-27 | $16.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $5.20M derived: sum of 2 quarters · filed 2023-02-27 | $9.70M derived: sum of 3 quarters · filed 2023-02-27 | $7.80M 10-K · filed 2023-02-27 |
| 2020-09-30 | $2.50M 10-Q · filed 2021-11-10 | $7.00M derived: sum of 2 quarters · filed 2021-11-10 | $5.10M 10-Q · filed 2021-11-10 | $7.20M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $4.50M 10-Q · filed 2021-08-11 | $5.80M 10-Q · filed 2021-08-11 | $4.70M derived: sum of 3 quarters · filed 2021-08-11 | $4.90M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $100.00K 10-Q · filed 2021-05-11 | $200.00K derived: sum of 2 quarters · filed 2021-05-11 | $400.00K derived: sum of 3 quarters · filed 2021-05-11 | $400.00K derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $300.00K derived: sum of 2 quarters · filed 2021-03-29 | $300.00K derived: sum of 3 quarters · filed 2021-03-29 | $300.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | $200.00K 10-Q · filed 2020-11-12 | $200.00K derived: sum of 2 quarters · filed 2020-11-12 | $200.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |